Genetic Analysis AS (GEAN) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Genetic Analysis AS NOK 0.08, price NOK 0.52, upside -85.3%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Genetic Analysis AS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range kr 0.4090 – kr 12.31 · fair‑value band kr 0.0510 – kr 0.0935 · the kr 0.5200 price screens above the kr 0.0765 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Genetic Analysis AS in your weekly email
Every Wednesday you see whether Genetic Analysis AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally.
Show more
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Fecal Test, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples. It is also involved in the operation of service laboratory where customers can send samples for microbiome profiling analysis; and provision of bioinformatic analysis and custom panel services. The company was founded in 2008 and is headquartered in Oslo, Norway.
Stock analysis
Genetic Analysis AS (GEAN) currently trades at kr 0.5200, while our model-based Fair Value estimate is kr 0.0765, implying the stock looks roughly 579.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.0510 (bear) to kr 0.0935 (bull), the price of kr 0.5200 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Genetic Analysis AS reported revenue of 16.7M NOK in FY2025 versus 6.8M NOK in FY2021, a compound +25.2%/yr. Reported net income was −11.4M NOK in FY2025.
Key figures
Market cap 46.0M NOK (≈ $4.8M) · P/S ratio 2.14 · EPS (TTM) kr −0.1600 · Net margin −68.3% · Return on equity −56.5% · Return on assets (EBIT) −34.8% · Operating margin −101% · Revenue (TTM) 21.5M NOK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −85%, GEAN screens richer than that median.
Fair Value models
Bear kr 0.0510Fair Value kr 0.0765Bull kr 0.0935
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−359.3% (2020) → −62.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−85% · Bottom 25%
Profitability
Return on assets−16% · Bottom 25%
Net margin (TTM)−53% · Bottom 25%
Operating margin (TTM)−101% · Bottom 25%
Growth and dividend
Revenue growth9% · Above median
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.18× · Cheapest 25%
P/S (TTM)0.23× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)47· sector 25
PAST (return on equity)0· sector 8
HEALTH (low debt)93· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Genetic Analysis AS Fair Value". https://www.fairvalue-calculator.com/stock/GEAN
Frequently asked questions
Is Genetic Analysis AS (GEAN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 0.0765 versus a price of kr 0.5200, about −85% upside (overvalued).
What is the fair value of GEAN?
Our model-based fair value for Genetic Analysis AS is kr 0.0765 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 0.5200.
What is the quality score of GEAN?
Genetic Analysis AS has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genetic Analysis AS (GEAN)?
Our model-based price target is the fair value of kr 0.0765 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario kr 0.0510, optimistic scenario kr 0.0935. It is a calculation from audited fundamentals, not an analyst target.
What is the Genetic Analysis AS stock forecast for 2026?
Our models put fair value at kr 0.0765, about −85% upside versus a price of kr 0.5200 (overvalued). Cautious scenario kr 0.0510, optimistic scenario kr 0.0935. The calculation is refreshed regularly with new filings.
What is the revenue of Genetic Analysis AS (GEAN)?
Genetic Analysis AS reported trailing-twelve-month revenue of about 21.5M NOK (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Genetic Analysis AS (GEAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genetic Analysis AS it is kr 0.0765 per share (as of Sep 23, 2026), against a price of kr 0.5200. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Genetic Analysis AS stock overvalued or undervalued in 2026?
As of Sep 23, 2026, GEAN trades above its calculated fair value: price kr 0.5200, fair value kr 0.0765, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GEAN?
No. The price is what the market pays today (kr 0.5200); the fair value is what the company's own numbers justify (kr 0.0765). For Genetic Analysis AS the two are kr 0.4435 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genetic Analysis AS worth?
The market values Genetic Analysis AS at about 46.0M NOK (market capitalisation, as of Sep 23, 2026). Per share that is kr 0.5200; our models calculate a fair value of kr 0.0765 per share.
What do the bullish and bearish scenarios say about GEAN?
Our models span a range for Genetic Analysis AS: cautious scenario kr 0.0510, base kr 0.0765, optimistic kr 0.0935 per share (as of Sep 23, 2026, price kr 0.5200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genetic Analysis AS (GEAN)?
Balance-sheet figures for Genetic Analysis AS (as of Sep 23, 2026): return on equity −56.5%, debt of 0.15 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is GEAN from its 52-week high?
Genetic Analysis AS trades at kr 0.5200, about 42% below its 52-week high of kr 0.9000 and 13% above the low of kr 0.4610 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0765 is for.
Which stocks are comparable to Genetic Analysis AS?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genetic Analysis AS stock attractive at the current price?
The data as of Sep 23, 2026: price kr 0.5200, calculated fair value kr 0.0765 (−85%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GEAN calculated?
We run Genetic Analysis AS through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0765, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Genetic Analysis AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genetic Analysis AS (GEAN)?
The closing price on Sep 23, 2026 was kr 0.5200. Our model-based fair value is kr 0.0765, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genetic Analysis AS right now?
The price sits above even our optimistic bull case (kr 0.0935). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.0510 to kr 0.0935) leaves room in how you read the outcome.
Key figures of Genetic Analysis AS
How large is the market capitalisation of Genetic Analysis AS (GEAN)?
The market capitalisation of Genetic Analysis AS is 46.0M NOK (≈ $4.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genetic Analysis AS (GEAN)?
The price-to-sales ratio of Genetic Analysis AS is 2.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genetic Analysis AS (GEAN)?
Earnings per share at Genetic Analysis AS are kr −0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genetic Analysis AS (GEAN)?
The net margin of Genetic Analysis AS is −68.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genetic Analysis AS (GEAN)?
The return on equity (ROE) of Genetic Analysis AS is −56.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genetic Analysis AS (GEAN)?
On an EBIT basis the return on assets of Genetic Analysis AS is −34.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genetic Analysis AS (GEAN)?
The operating margin of Genetic Analysis AS is −101% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genetic Analysis AS (GEAN)?
Revenue at Genetic Analysis AS is growing +9.4% versus a year earlier (3y avg +14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genetic Analysis AS (GEAN) generate?
The free cash flow of Genetic Analysis AS is −3.1M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Genetic Analysis AS in the live analysis
One click puts Genetic Analysis AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
